CD8A and neoplasm: Moreover, patients receiving anti‐PD‐1 neoadjuvant therapy had fewer tumor‐infiltrating CD8+CK2B+ T cells than those who did not receive neoadjuvant therapy (P < 0.01) (Figure 1G).